post roughli in-lin result mark solid us pharmaci
perform despit on-going reimburs pressur challeng retail
environ headwind unlik abat near term cost
manag program strateg partnership on-going digital/it suppli
chain invest help increas effici provid off-set lastli
compani continu gener solid cash flow provid flexibl on-going
investment/strateg deploy maintain hold rate price
wholesal revenu came shi estim
in-lin retail pharmaci usa perform off-set weaker
expect revenu retail pharmaci vs strhe
wholesal vs strhe wholesal
heavili impact currenc cc sale strong driven
perform emerg market adjust oper incom
within retail pharmaci adjust script count
think strhe tie larg store closur comp growth
better acceler sequenti revenu per script also ahead
think brand inflat specialti growth retail sale remain tepid
sale ss sale impact de-
emphasi tobacco bp off-set benefit cough/cold season
bp adjust ep ahead estim aid
lower tax rate share count
transform manag program progress compani
remain target gener annual cost save
smart spend benchmark headcount reduct complet
compani focus digit effort includ optim vendor
microsoft cloud migrat addit manag launch
uk portfolio optim program help mitig effect challeng
oper environ plan close store store count
next month given mani plan closur smaller
squar footag profit within walk distanc
anoth boot locat compani expect revenu impact minim
 store optim program nr
integr also track plan store closur
complet store success convert custom retent
store closur thu far encourag compani expect
integr process complet end final
compani continu progress retail core suppli chain
revamp see opportun increas visibl around inventori
work capit manag time
tr target
partnership digit effort walgreen continu expand strateg collabor
announc new partnership villagemd collabor villagemd
open five primari care clinic next exist walgreen store houston area expect
open end villag medic walgreen locat provid conveni
primari care offer work collabor pharmacist well nurs social
worker meet patient need addit labcorp lh buy partnership continu
progress labcorp walgreen locat expect open year earli feedback
collabor kr nr posit final digit solut continu gain
traction mobil app download yoy retail refil script initi digit channel
balanc reward member manag up expect digit
invest
retail pharmaci wholesal detail retail pharmaci revenu
came tie currenc head wind continu challeng
uk constant currenc basi sale weak boot uk result ss
pharmaci sale increas ss retail sale despit boot uk share gain
pharmaci wholesal revenu touch due advers
currenc impact cc basi sale strong increas driven emerg market
detail reiter guidanc cffo came think
vs strhe trend remain solid despit hand
headwind integration/optim program w/c increas cash tax compani also
complet share repurchas bring ytd total manag reiter full
year adjust ep guidanc expect roughli flat constant currenc basi fine
tune estim respect
price target unchang
page
revenu
revenu
revenu
net incom
non-gaap add back tax
adjust net incom
page
inc global leader pharmaceut servic industri us
store sizabl wholesale/distribut network countri compani largest retail
pharmaci unit state retail pharmaci usa divis gener total
compani revenu remain sale come retail intern pharmaci
wholesal
continu view trend pharmaceut servic solid given age popul util
growth increas specialti demand expect reimbursement/th impact gener remain
remain headwind fo forese futur believ portfolio strateg partnership
collabor labcorp demonstr valu compani scale/
capabl provid on-going volum tailwind reason optim
challeng exist retail pharmaci busi continu see margin pressur tie sever
factor rate price pressur payer contract increasingli difficult overal retail
valuat risk
hold rate price target base stock trade adjust cash
ep modestli ahead current multipl continu see solid underli trend
pharmaceut servic view compani scale key differenti like compani free
cash flow gener view risk/reward balanc given us pharmaci margin pressur
like linger difficult retail environ upsid risk price target includ stronger core
trend dissip reimburs pressur aggress capit deploy downsid risk
includ increas price pressur addit retail competit
compani mention note
laboratori corpor america hold lh buy david macdonald
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
